JP2005522433A5 - - Google Patents

Download PDF

Info

Publication number
JP2005522433A5
JP2005522433A5 JP2003565527A JP2003565527A JP2005522433A5 JP 2005522433 A5 JP2005522433 A5 JP 2005522433A5 JP 2003565527 A JP2003565527 A JP 2003565527A JP 2003565527 A JP2003565527 A JP 2003565527A JP 2005522433 A5 JP2005522433 A5 JP 2005522433A5
Authority
JP
Japan
Prior art keywords
composition according
pharmaceutical composition
nucleic acid
salt
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003565527A
Other languages
English (en)
Japanese (ja)
Other versions
JP4613011B2 (ja
JP2005522433A (ja
Filing date
Publication date
Priority claimed from FR0201584A external-priority patent/FR2835749B1/fr
Application filed filed Critical
Publication of JP2005522433A publication Critical patent/JP2005522433A/ja
Publication of JP2005522433A5 publication Critical patent/JP2005522433A5/ja
Application granted granted Critical
Publication of JP4613011B2 publication Critical patent/JP4613011B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2003565527A 2002-02-08 2003-02-07 invivo遺伝子伝達を改善する医薬組成物 Expired - Lifetime JP4613011B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0201584A FR2835749B1 (fr) 2002-02-08 2002-02-08 Composition pharmaceutique ameliorant le transfert de gene in vivo
PCT/FR2003/000407 WO2003066104A2 (fr) 2002-02-08 2003-02-07 Composition pharmaceutique ameliorant le transfert de gene in vivo

Publications (3)

Publication Number Publication Date
JP2005522433A JP2005522433A (ja) 2005-07-28
JP2005522433A5 true JP2005522433A5 (https=) 2006-03-16
JP4613011B2 JP4613011B2 (ja) 2011-01-12

Family

ID=27620039

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003565527A Expired - Lifetime JP4613011B2 (ja) 2002-02-08 2003-02-07 invivo遺伝子伝達を改善する医薬組成物

Country Status (10)

Country Link
US (2) US7709452B2 (https=)
EP (1) EP1471944B1 (https=)
JP (1) JP4613011B2 (https=)
AT (1) ATE326986T1 (https=)
AU (1) AU2003222896A1 (https=)
CA (1) CA2473212C (https=)
DE (1) DE60305443T2 (https=)
ES (1) ES2265569T3 (https=)
FR (1) FR2835749B1 (https=)
WO (1) WO2003066104A2 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2868953B1 (fr) * 2004-04-16 2006-06-30 Inst Nat Sante Rech Med Composition pour le transfert intracellulaire d'un acide nucleique.
EP2076257A4 (en) * 2006-09-15 2014-04-16 Belrose Pharma Inc POLYMER CONJUGATES WITH POSITIVELY LOADED PARTS
DE102006051623A1 (de) 2006-11-02 2008-07-31 Horn, Peter A. Verfahren und Stoffgemisch zur Verbesserung eines in vivo Genfransfers
US8790664B2 (en) 2008-09-05 2014-07-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Multimodular assembly useful for intracellular delivery
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2013120302A (ru) 2010-10-01 2014-11-20 Модерна Терапьютикс, Инк. Сконструированные нуклеиновые кислоты и способы их применения
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2648950C2 (ru) 2011-10-03 2018-04-02 Модерна Терапьютикс, Инк. Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
CN104114572A (zh) 2011-12-16 2014-10-22 现代治疗公司 经修饰的核苷、核苷酸和核酸组合物
WO2013106558A1 (en) 2012-01-10 2013-07-18 Merial Limited Lipid based adjuvants for dna - plasmid vaccines
WO2013128424A1 (en) 2012-03-02 2013-09-06 Institut National De La Sante Et De La Recherche Medicale Vaccine for prophylaxis or treatment of an allergen-driven and/or a chronic airways disease
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
AU2013243948A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US20150182620A1 (en) 2012-06-15 2015-07-02 Inserm (Institut De La Sante Et De La Recherche Medicale) Polypeptides for use in the Prophylactic Treatment of Allergic Asthma
WO2014081507A1 (en) 2012-11-26 2014-05-30 Moderna Therapeutics, Inc. Terminally modified rna
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
JP2016538829A (ja) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. 低密度リポタンパク質受容体をコードするポリヌクレオチド
JP6774878B2 (ja) * 2014-04-01 2020-10-28 アンスティチュート ナショナル デ ラ サンテ エ デ ラ レシェルシュ メディカル(アンセルム) Rnaの細胞内送達のための、キャップされた及びキャップされていないrna分子およびブロックコポリマー
EP3225246A1 (en) 2016-03-31 2017-10-04 Klinikum der Universität München Synthetic compound for improving efficiency of transfection
US20210000917A1 (en) 2018-03-05 2021-01-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and composition for the treatment of allergic asthma
AU2020234003B2 (en) * 2019-03-11 2026-02-12 Evaxion A/S Nucleic acid vaccination using neo-epitope encoding constructs
AU2021202658A1 (en) 2021-04-28 2022-11-17 Fondazione Telethon Gene therapy
GB202206346D0 (en) 2022-04-29 2022-06-15 Ospedale San Raffaele Srl Gene therapy
EP4704818A1 (en) 2023-03-30 2026-03-11 Vivadju Pvax14 nucleic acid in combination with all-trans retinoic acid (atra) and a checkpoint inhibitor for the treatment of cancer
EP4704856A1 (en) 2023-03-30 2026-03-11 Vivadju Pvax14 nucleic acid formulated with nano-vehicle in combination with all-trans retinoic acid (atra) for activating immune pathways
WO2025129128A1 (en) 2023-12-15 2025-06-19 Vivasor, Inc. Compositions and methods for non-viral delivery of therapeutic compounds

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5470568A (en) * 1992-02-13 1995-11-28 Arch Development Corporation Methods and compositions of a polymer (poloxamer) for cell repair
GB9216082D0 (en) * 1992-07-28 1992-09-09 Univ Nottingham Lymphatic delivery composition
US5656611A (en) * 1994-11-18 1997-08-12 Supratek Pharma Inc. Polynucleotide compositions
US6359054B1 (en) * 1994-11-18 2002-03-19 Supratek Pharma Inc. Polynucleotide compositions for intramuscular administration
US6221959B1 (en) * 1994-11-18 2001-04-24 Supratek Pharma, Inc. Polynucleotide compositions
US6040295A (en) * 1995-01-13 2000-03-21 Genemedicine, Inc. Formulated nucleic acid compositions and methods of administering the same for gene therapy
JP2003528024A (ja) * 1997-12-16 2003-09-24 バレンティス・インコーポレーテッド 製剤化された核酸分子の無針注入
GB9904627D0 (en) * 1999-03-02 1999-04-21 Danbiosyst Uk Polymer compositions for polynucleotide delivery
WO2001005913A1 (en) 1999-07-16 2001-01-25 Reatech Phosphor addition in gasification
AU6389000A (en) * 1999-07-28 2001-02-19 Valentis, Inc. Sonoporation of tumors
AU2001238485A1 (en) * 2000-02-18 2001-08-27 The Immune Response Corporation Methods and compositions for gene delivery
CA2401239A1 (en) * 2000-03-03 2001-09-13 Valentis, Inc. Improved poloxamer and poloxamine compositions for nucleic acid delivery
WO2002061040A2 (en) * 2000-10-20 2002-08-08 Valentis, Inc. Gene delivery formulations and methods for treatment of ischemic conditions

Similar Documents

Publication Publication Date Title
JP2005522433A5 (https=)
US12173284B2 (en) Modified guide RNAs
Sharma et al. Versatility of peptide nucleic acids (PNA s): Role in chemical biology, drug discovery, and origins of life
JP6767976B2 (ja) 関節疾患の治療のためのメッセンジャーrna治療法
CA2919226C (en) Compositions and methods for delivering messenger rna
CN102177237B (zh) 用于贮存和稳定生物分子的基质和介质
TW202028460A (zh) 用於乳酸脫氫酶(ldha)基因編輯之組合物及方法
CN117487776A (zh) Casz组合物和使用方法
US20190142857A1 (en) Methods
FR2835749B1 (fr) Composition pharmaceutique ameliorant le transfert de gene in vivo
CN1104423A (zh) 杀菌-消毒的去污组合物
KR20130051954A (ko) 베타-ENaC-관련 질환을 치료하기 위한 유기 조성물
US5132207A (en) Accelerated nucleic acid reassociation method
CN117396193A (zh) 用于递送rna的组合物和方法
WO2003101394A3 (en) Defensins: use as antiviral agents
Kırıcı et al. Purification of carbonic anhydrase from Capoeta umbla (Heckel, 1843) gills and toxicological effects of some metals on enzyme activity
US9492470B2 (en) Use of HMGA-targeted phosphorothioate DNA aptamers to suppress carcinogenic activity and increase sensitivity to chemotherapy agents in human cancer cells
US20240384269A1 (en) Compositions containing nucleic acid nanoparticles and processes related to alteration of their physiochemical characteristics
CN101422152B (zh) 一种复合杀生剂
SG194626A1 (en) A method for manufacturing pegylated oligonucleotides
JP3289912B2 (ja) ポリアミノ酸オリゴヌクレオチドキャリヤー
Hollstein et al. Inhibition of ribonucleic acid synthesis by myxin
JP2012509904A (ja) 核酸送達組成物および核酸送達法
JPH10158196A (ja) 核酸安定化用キャリアー
Poddar et al. ZIF polymorphs for nucleic acid delivery and targeted knockdown of gene expression in prostate cancer